Thursday, June 11, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 108 of 1,261
  1. US 12031132

    Systems and methods for the treatment of hemoglobinopathies

    Editas Medicine, Inc. Β· Granted Jul 9, 2024 Β· Expires Jul 4, 2044

    granted
  2. US 12030953

    Chimeric antigen receptors, compositions, and methods

    Regents of the University of Minnesota Β· Granted Jul 9, 2024 Β· Expires Jul 4, 2044

    granted
  3. US 12029732

    Treatment of vascular and lymphatic disease

    The Regents of the University of Colorado, a Body Corporate Β· Granted Jul 9, 2024 Β· Expires Jul 4, 2044

    granted
  4. US 12031136

    Treatment for skeletal diseases caused by intracellular protein trafficking defects

    The Board of Regents of the University of Oklahoma Β· Granted Jul 9, 2024 Β· Expires Jul 4, 2044

    granted
  5. WO 2024141977

    CELLULES TUEUSES NATURELLES MODIFIÉES ET PROCÉDÉS ASSOCIÉS

    ASTELLAS PHARMA INC [JP] Β· Granted Jul 4, 2024 Β· Expires Jun 29, 2044

    granted
  6. US 12023383

    Lipid compositions

    ARBUTUS BIOPHARMA CORPORATION Β· Granted Jul 2, 2024 Β· Expires Jun 27, 2044

    granted
  7. US 12023394

    Vesicle-coated fibers made from crosslinked lipids

    The Regents of the University of California Β· Granted Jul 2, 2024 Β· Expires Jun 27, 2044

    granted
  8. US 12024505

    Heterocyclic compounds useful as modulators of acetylcholine receptors

    Takeda Pharmaceutical Company Limited Β· Granted Jul 2, 2024 Β· Expires Jun 27, 2044

    granted
  9. US 12024570

    Anti-CTLA-4 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. Β· Granted Jul 2, 2024 Β· Expires Jun 27, 2044

    granted
  10. US 12024509

    Therapeutic compounds as inhibitors of the orexin-1 receptor

    C4X Discovery Limited Β· Granted Jul 2, 2024 Β· Expires Jun 27, 2044

    granted
  11. US 12023348

    EGR1 targeting molecules for the treatment of inflammatory and hyperproliferative conditions

    The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center Β· Granted Jul 2, 2024 Β· Expires Jun 27, 2044

    granted
  12. US 12023410

    Micro/nanobubble solutions for tissue preservation and generation thereof

    The Regents of the University of California Β· Granted Jul 2, 2024 Β· Expires Jun 27, 2044

    granted
  13. US 12023391

    Alpha(v)beta(6) integrin-binding peptides and methods of use thereof

    The Regents of the University of California Β· Granted Jul 2, 2024 Β· Expires Jun 27, 2044

    granted
  14. US 12023359

    Phospholipid compositions for delivery of therapeutic compounds

    Aker BioMarine Human Ingredients AS Β· Granted Jul 2, 2024 Β· Expires Jun 27, 2044

    granted
  15. US 12023309

    Enhanced delivery epinephrine compositions

    Aquestive Therapeutics, Inc. Β· Granted Jul 2, 2024 Β· Expires Jun 27, 2044

    granted
  16. US 12023389

    Compositions that target tumor-associated macrophages and methods of use therefor

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE Β· Granted Jul 2, 2024 Β· Expires Jun 27, 2044

    granted
  17. US 12024486

    Lipocationic dendrimers and uses thereof

    The Board of Regents of the University of Texas System Β· Granted Jul 2, 2024 Β· Expires Jun 27, 2044

    granted
  18. US 12023335

    Method for treating pancreatic cancer

    PTC THERAPEUTICS, INC. Β· Granted Jul 2, 2024 Β· Expires Jun 27, 2044

    granted
  19. US 12024556

    Anti-Staphylococcus antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. Β· Granted Jul 2, 2024 Β· Expires Jun 27, 2044

    granted
  20. US 12023343

    Thermo-kinetic mixing for pharmaceutical applications

    The Board of Regents of the University of Texas System Β· Granted Jul 2, 2024 Β· Expires Jun 27, 2044

    granted
  21. US 12023337

    Methods of treating cancer

    Corvus Pharmaceuticals, Inc. Β· Granted Jul 2, 2024 Β· Expires Jun 27, 2044

    granted
  22. US 12024512

    Cocrystal

    Takeda Pharmaceutical Company Limited Β· Granted Jul 2, 2024 Β· Expires Jun 27, 2044

    granted
  23. US 12025615

    Methods of classifying response to immunotherapy for cancer

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY Β· Granted Jul 2, 2024 Β· Expires Jun 27, 2044

    granted
  24. US 12024718

    Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. Β· Granted Jul 2, 2024 Β· Expires Jun 27, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.